Shop
eStoreRx™
Online Supplement Dispensary
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
Biotics Research is proud to expand our commitment to education with the Wellness Unfiltered Pro Podcast. Each episode delves into key health topics and the clinical applications of our premier products. Through candid, insightful conversations, our team offers practical guidance to keep you informed and empowered as a healthcare professional.
December 20 2024
The British Journal of Sports Medicine recently published a systematic review that analyzed the effects of postpartum exercise on maternal postpartum ...
The Journal of Obesity & Metabolic Syndrome recently published the results of a randomized, double-blind, and placebo-controlled clinical trial evaluating the supplementation of silymarin among participants with metabolic dysfunction-associated steatotic liver disease (MASLD). This recent nomenclature, MASLD, applies to people with steatotic liver disease that is attributed to the metabolic syndrome; it has considerable overlap with metabolic dysfunction-association fatty liver disease (MAFLD), and is recognized to be the leading cause of chronic liver disease and liver-related morbidity/mortality.
This 24-week trial took place in China and assigned 83 participants to either placebo or 103.2 mg/day silymarin (split into two daily doses, given at breakfast and dinner). The primary outcomes were markers of liver health, including liver stiffness, hepatic steatosis, and liver function, with M probe vibration-controlled transient elastography (VCTE, FibroScan) utilized to assess steatosis and stiffness. A number of markers of metabolic health were included as secondary outcomes, including body composition and glucose and lipid profiles, as well as 16S rRNA sequencing of fecal samples.
Compared to baseline participants receiving silymarin had a significant reduction in liver stiffness (-0.21 kPa) while people receiving placebo had a tendency to increase (+0.41 kPa). Significant reductions in serum γ-glutamyl transpeptidase (GGT) and ApoB also occurred with silymarin, in contrast to increases with placebo. No other significant differences were observed, although silymarin was linked to changes in the gut microbiome, specifically to increased species diversity and enrichment of Oscillospiraceae and decreased Selenomonadaceae abundance. Oscillospiraceae species may have the ability to metabolize complex carbohydrates and synthesize short-chain fatty acids, suggesting a possible gut-liver axis for the observed benefits. Overall, this study supports a protective effect of silymarin against liver stiffness at fairly low doses, as well as reductions in GGT and ApoB (both associated with overall mortality in multiple other studies), in support of a recent meta-analysis evaluating polyphenol use for NAFLD.
Submit this form and you'll receive our latest news and updates.
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment